Literature DB >> 28712885

Detection of CFTR function and modulation in primary human nasal cell spheroids.

John J Brewington1, Erin T Filbrandt2, F J LaRosa2, Alicia J Ostmann2, Lauren M Strecker2, Rhonda D Szczesniak3, John P Clancy2.   

Abstract

BACKGROUND: Expansion of CFTR modulators to patients with rare/undescribed mutations will be facilitated by patient-derived models quantifying CFTR function and restoration. We aimed to generate a personalized model system of CFTR function and modulation using non-surgically obtained nasal epithelial cells (NECs).
METHODS: NECs obtained by curettage from healthy volunteers and CF patients were expanded and grown in 3-dimensional culture as spheroids, characterized, and stimulated with cAMP-inducing agents to activate CFTR. Spheroid swelling was quantified as a proxy for CFTR function.
RESULTS: NEC spheroids recapitulated characteristics of pseudostratified respiratory epithelia. When stimulated with forskolin/IBMX, spheroids swelled in the presence of functional CFTR, and shrank in its absence. Spheroid swelling quantified mutant CFTR restoration in F508del homozygous cells using clinically available CFTR modulators.
CONCLUSIONS: NEC spheroids hold promise for understanding rare CFTR mutations and personalized modulator testing to drive evaluation for CF patients with common, rare or undescribed mutations. Portions of this data have previously been presented in abstract form at the 2016 meetings of the American Thoracic Society and the 2016 North American Cystic Fibrosis Conference.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CFTR; Modulator; Organoid; Personalized model system

Mesh:

Substances:

Year:  2017        PMID: 28712885      PMCID: PMC5868354          DOI: 10.1016/j.jcf.2017.06.010

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  22 in total

Review 1.  Evidence for airway surface dehydration as the initiating event in CF airway disease.

Authors:  R C Boucher
Journal:  J Intern Med       Date:  2007-01       Impact factor: 8.989

2.  An apical-membrane chloride channel in human tracheal epithelium.

Authors:  M J Welsh
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

3.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

4.  A bioassay using intestinal organoids to measure CFTR modulators in human plasma.

Authors:  R Dekkers; L A W Vijftigschild; A M Vonk; E Kruisselbrink; K M de Winter-de Groot; H M Janssens; C K van der Ent; J M Beekman
Journal:  J Cyst Fibros       Date:  2014-11-06       Impact factor: 5.482

5.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

Review 6.  Personalized medicine for cystic fibrosis: establishing human model systems.

Authors:  Hongmei Mou; Karissa Brazauskas; Jayaraj Rajagopal
Journal:  Pediatr Pulmonol       Date:  2015-10

Review 7.  Role of CFTR in airway disease.

Authors:  J M Pilewski; R A Frizzell
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

8.  Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.

Authors:  Puay-Wah Phuan; Guido Veit; Joseph A Tan; Walter E Finkbeiner; Gergely L Lukacs; A S Verkman
Journal:  Mol Pharmacol       Date:  2015-08-05       Impact factor: 4.436

9.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Authors:  Michael P Boyle; Scott C Bell; Michael W Konstan; Susanna A McColley; Steven M Rowe; Ernst Rietschel; Xiaohong Huang; David Waltz; Naimish R Patel; David Rodman
Journal:  Lancet Respir Med       Date:  2014-06-24       Impact factor: 30.700

10.  Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function.

Authors:  John P Clancy; Rhonda D Szczesniak; Melissa A Ashlock; Sarah E Ernst; Lijuan Fan; Douglas B Hornick; Philip H Karp; Umer Khan; James Lymp; Alicia J Ostmann; Amir Rezayat; Timothy D Starner; Shajan P Sugandha; Hongtao Sun; Nancy Quinney; Scott H Donaldson; Steven M Rowe; Sherif E Gabriel
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more
  25 in total

1.  Correlation between Ivacaftor-induced CFTR Activation in Airway Epithelial Cells and Improved Lung Function: A Proof-of-Concept Study.

Authors:  Jason S Debley; Kaitlyn A Barrow; Lucille M Rich; Pradeep Singh; Edward F McKone; David P Nichols
Journal:  Ann Am Thorac Soc       Date:  2020-08

2.  Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study.

Authors:  John J Brewington; Erin T Filbrandt; Francis J LaRosa; Jessica D Moncivaiz; Alicia J Ostmann; Lauren M Strecker; John P Clancy
Journal:  J Vis Exp       Date:  2018-04-11       Impact factor: 1.355

3.  A simple method to generate human airway epithelial organoids with externally orientated apical membranes.

Authors:  Carolin A Boecking; Peter Walentek; Lorna T Zlock; Dingyuan I Sun; Paul J Wolters; Hiroaki Ishikawa; Byung-Ju Jin; Peter M Haggie; Wallace F Marshall; Alan S Verkman; Walter E Finkbeiner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-01-26       Impact factor: 5.464

4.  Mouse lung organoid responses to reduced, increased, and cyclic stretch.

Authors:  Rashika Joshi; Matthew R Batie; Qiang Fan; Brian M Varisco
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-01       Impact factor: 5.464

Review 5.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

Review 6.  CFTR modulator theratyping: Current status, gaps and future directions.

Authors:  John Paul Clancy; Calvin U Cotton; Scott H Donaldson; George M Solomon; Donald R VanDevanter; Michael P Boyle; Martina Gentzsch; Jerry A Nick; Beate Illek; John C Wallenburg; Eric J Sorscher; Margarida D Amaral; Jeffrey M Beekman; Anjaparavanda P Naren; Robert J Bridges; Philip J Thomas; Garry Cutting; Steven Rowe; Anthony G Durmowicz; Martin Mense; Kris D Boeck; William Skach; Christopher Penland; Elizabeth Joseloff; Hermann Bihler; John Mahoney; Drucy Borowitz; Katherine L Tuggle
Journal:  J Cyst Fibros       Date:  2018-06-20       Impact factor: 5.482

7.  Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies.

Authors:  John J Brewington; Erin T Filbrandt; F J LaRosa; Jessica D Moncivaiz; Alicia J Ostmann; Lauren M Strecker; John P Clancy
Journal:  JCI Insight       Date:  2018-07-12

Review 8.  Nasal Epithelial Cell-Based Models for Individualized Study in Cystic Fibrosis.

Authors:  Duncan E Keegan; John J Brewington
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

9.  Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations.

Authors:  Matthew S McCravy; Nancy L Quinney; Deborah M Cholon; Susan E Boyles; Timothy J Jensen; Andrei A Aleksandrov; Scott H Donaldson; Peadar G Noone; Martina Gentzsch
Journal:  Eur Respir J       Date:  2020-07-30       Impact factor: 16.671

Review 10.  Recent progress in translational cystic fibrosis research using precision medicine strategies.

Authors:  Deborah M Cholon; Martina Gentzsch
Journal:  J Cyst Fibros       Date:  2017-10-04       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.